Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
Axel Grothey, Eric Van Cutsem, Alberto Sobrero, Salvatore Siena, Alfredo Falcone, Marc Ychou, Yves Humblet, Olivier Bouche, Laurent Mineur, Carlo Barone, Antoine Adenis, Josep Tabernero, Takayuki Yoshino, Heinz-Josef Lenz, Richard M Goldberg, Daniel J Sargent, Frank Cihon, Lisa Cupit, Andrea Wagner, Dirk Laurent
The Lancet | ELSEVIER SCIENCE INC | Published : 2013
Bayer HealthCare Pharmaceuticals.The Mayo Foundation has received research funding for clinical studies done by AG from Genentech, Sanofi, Bayer, Daiichi, and Imclone and has received honoraria for consulting activities of AG for Genentech, Roche, Onyx, Bayer, Imclone, Bristol-Myers Squibb, and Sanofi. EVC has received research funding from Bayer. AS has been an advisory board member and has spoken at symposia for Roche, Merck, Bayer, Amgen, and Sanofi. SS has been an advisory board member for Amgen, AstraZeneca, Bayer, Genentech, Merck Serono, Roche, and Sanofi. AF has received honoraria from Amgen, Bayer, Merck Serono, Roche, and Sanofi for speaking, consultancy, and advisory board membership, and has received research support from Amgen, Bayer, Merck Serono, Roche, and Sanofi. MY has received honoraria from Bayer for advisory board membership. YH has received honoraria from Bayer to act as a consultant and has received research funding from Bayer. OB has received honoraria from Roche, Merck Serono, and Amgen. LM declares that he has no conflicts of interest. CB has received honoraria for lecturing and advisory board membership from Bayer, Merck, Roche, and Novartis, and has received honoraria for lecturing from GlaxoSmithKline and Amgen. AA has received honoraria from Bayer (conference and research funding). JT has been a consultant and advisory board member for Amgen, Bristol-Myers Squibb, Genentech, Merck KGaA, Millennium, Novartis, Onyx, Pfizer, Roche, Sanofi, and Bayer and has received honoraria from Amgen, Merck KGaA, Novartis, Roche, and Sanofi. TY has received consulting fees from Takeda, honoraria from Chugai, Takeda, Yakult, Bristol-Myers Squibb, and Merck Serono, and research funding from Daiichi Sankyo, Taiho, Bayer, and Imclone. H-JL has been an advisory board member for Bayer. RMG has received research support to Ohio State University from Sanofi, Bayer, Myriad, and Jennerex, has provided unpaid consultancy for Bayer and Sanofi, and has received payment from Lilly for participation in a data safety monitoring board. DJS has received consulting fees from the CORRECT steering committee (less than $5000/year). FC, LC, AW, and DL are employees of Bayer. FC and DL have Bayer stock ownership.